Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleDelta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo.
Author(s)Frytak S, Moertel CG, O'Fallon JR, Rubin J, Creagan ET, O'Connell MJ, Schutt AJ, Schwartau NW
Journal, Volume, IssueAnnals of Internal Medicine 1979;91(6):825-830
Major outcome(s)THC and PCP equally effective; both better than placebo; THC produced psychic effects in 82%
IndicationNausea/vomiting;Cancer;Cancer chemotherapyAbstract
MedicationDelta-9-THC

The antiemetic activity and side-effects of delta-9- tetrahydrocannabinol (THC) were evaluated in 116 patients (median age 61 years) receiving combined 5-fluorouracil and semustine (methyl CCNU) therapy for gastrointestinal carcinoma. In a double-blind study, patients were randomized to receive THC, 15 mg orally three times a day, prochlorperazine, 10 mg orally three times a day, or placebo. The THC had superior antiemetic activity in comparison to placebo, but it showed no advantage over prochlorperazine. Central nervous system side-effects, however, were significantly more frequent and more severe with THC. With the dosage and schedule we used, and in our patient population of largely elderly adults, THC therapy resulted in an overall more unpleasant treatment experience than that noted with prochlorperazine or placebo. Although THC may have a role in preventing nausea and vomiting associated with cancer chemotherapy, this role must be more clearly defined before THC can be recommended for general use.

Route(s)Oral
Dose(s)3 x 15 mg every 4 hours
Duration (days)several days
Participants116 cancer patients
DesignControlled study
Type of publication
Address of author(s)Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA
Full text

[Back to Overview]  [IACM Homepage]


up